{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:48:02Z","timestamp":1788220082492,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10067-021-05815-3","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T20:02:30Z","timestamp":1623873750000},"page":"3143-3151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4030-8793","authenticated-orcid":false,"given":"Shuji","family":"Asai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobunori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Nishiume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hanabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mochihito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Terabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Imagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"5815_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, M\u00fcller-Ladner U, Mysler EF, da Silva JAP, Po\u00f3r G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"5815_CR2","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O\u2019Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"5815_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landew\u00e9 R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413","journal-title":"Ann Rheum Dis"},{"key":"5815_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13075-016-1151-6","volume":"18","author":"E Nikiphorou","year":"2016","unstructured":"Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk-Hustings Y, Dixon WG, Hyrich KL, Askling J, Gossec L (2016) Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther 18:251","journal-title":"Arthritis Res Ther"},{"key":"5815_CR5","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1136\/annrheumdis-2012-201519","volume":"71","author":"P Studenic","year":"2012","unstructured":"Studenic P, Smolen JS, Aletaha D (2012) Near misses of ACR\/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 71:1702\u20131705","journal-title":"Ann Rheum Dis"},{"key":"5815_CR6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/rheumatology\/ker425","volume":"51","author":"M Vermeer","year":"2012","unstructured":"Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HL, van Riel PL, van de Laar MA (2012) The provisional ACR\/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford) 51:1076\u20131080","journal-title":"Rheumatology (Oxford)"},{"key":"5815_CR7","doi-asserted-by":"publisher","first-page":"R221","DOI":"10.1186\/ar4421","volume":"15","author":"E Balogh","year":"2013","unstructured":"Balogh E, Madruga Dias J, Orr C, Mullan R, Harty L, FitzGerald O, Gallagher P, Molloy M, O\u2019Flynn E, Kelly A, Minnock P, O\u2019Neill M, Moore L, Murray M, Fearon U, Veale DJ (2013) Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. Arthritis Res Ther 15:R221","journal-title":"Arthritis Res Ther"},{"key":"5815_CR8","doi-asserted-by":"publisher","first-page":"e003554","DOI":"10.1136\/bmjopen-2013-003554","volume":"3","author":"B Svensson","year":"2013","unstructured":"Svensson B, Andersson ML, Bala SV, Forslind K, Hafstr\u00f6m I, group Bs (2013) Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open 3:e003554","journal-title":"BMJ Open"},{"key":"5815_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24237","author":"RJO Ferreira","year":"2020","unstructured":"Ferreira RJO, Fautrel B, Saraux A, Gaujoux-Viala C, Rat AC, Guillemin F, da Silva JAP, Dougados M, Gossec L (2020) Patient global assessment and radiographic progression in early arthritis: 3-year results from the ESPOIR cohort. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.24237","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5815_CR10","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298\u20135307","journal-title":"J Immunol"},{"key":"5815_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74:333\u2013340","journal-title":"Ann Rheum Dis"},{"key":"5815_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88\u201395","journal-title":"Ann Rheum Dis"},{"key":"5815_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506\u2013517","journal-title":"Arthritis Rheumatol"},{"key":"5815_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"5815_CR15","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar1916","volume":"8","author":"T Kishimoto","year":"2006","unstructured":"Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8(Suppl 2):S2","journal-title":"Arthritis Res Ther"},{"key":"5815_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3109\/s10165-012-0782-y","volume":"23","author":"T Kojima","year":"2013","unstructured":"Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N (2013) Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol 23:977\u2013985","journal-title":"Mod Rheumatol"},{"key":"5815_CR17","first-page":"000496","volume":"3","author":"V Strand","year":"2017","unstructured":"Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Gabay C, Kavanaugh A, Jones G (2017) Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. RMD Open 3:000496","journal-title":"RMD Open"},{"key":"5815_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/rheumatology\/keu302","volume":"54","author":"T Kojima","year":"2015","unstructured":"Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N (2015) Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford) 54:113\u2013120","journal-title":"Rheumatology (Oxford)"},{"key":"5815_CR19","doi-asserted-by":"publisher","first-page":"21907","DOI":"10.1038\/s41598-020-78925-8","volume":"10","author":"N Takahashi","year":"2020","unstructured":"Takahashi N, Asai S, Kobayakawa T, Kaneko A, Watanabe T, Kato T, Nishiume T, Ishikawa H, Yoshioka Y, Kanayama Y, Hirano Y, Hanabayashi M, Yabe Y, Yokota Y, Suzuki M, Sobue Y, Terabe K, Ishiguro N, Kojima T (2020) Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. Sci Rep 10:21907","journal-title":"Sci Rep"},{"key":"5815_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"5815_CR21","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M\u00e9nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk\u00fd J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"5815_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68:954\u2013960","journal-title":"Ann Rheum Dis"},{"key":"5815_CR23","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/sim.3150","volume":"27","author":"PC Austin","year":"2008","unstructured":"Austin PC (2008) A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27:2037\u20132049","journal-title":"Stat Med"},{"key":"5815_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399\u2013424","journal-title":"Multivariate Behav Res"},{"key":"5815_CR25","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","volume":"41","author":"DT Felson","year":"1998","unstructured":"Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP (1998) Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41:1564\u20131570","journal-title":"Arthritis Rheum"},{"key":"5815_CR26","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71:1788\u20131800","journal-title":"Arthritis Rheumatol"},{"key":"5815_CR27","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, Zhang Y, Martin N, Xavier RM (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383:1511\u20131521","journal-title":"N Engl J Med"},{"key":"5815_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:234\u2013243","journal-title":"Nat Rev Rheumatol"},{"key":"5815_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 17:78","journal-title":"Nat Rev Drug Discov"},{"key":"5815_CR30","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1136\/annrheumdis-2011-201142","volume":"71","author":"NA Khan","year":"2012","unstructured":"Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C, Cazzato M, G\u00e9her P, Gossec L, Henrohn D, Hetland ML, Inanc N, Jacobs JW, Kerzberg E, Majdan M, Oyoo O, Peredo-Wende RA, Selim ZI, Skopouli FN, Sulli A, H\u00f8rslev-Petersen K, Taylor PC, Sokka T, group Q-R (2012) Patient\u2019s global assessment of disease activity and patient\u2019s assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? Ann Rheum Dis 71:1942\u20131949","journal-title":"Ann Rheum Dis"},{"key":"5815_CR31","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/art.34543","volume":"64","author":"P Studenic","year":"2012","unstructured":"Studenic P, Radner H, Smolen JS, Aletaha D (2012) Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 64:2814\u20132823","journal-title":"Arthritis Rheum"},{"key":"5815_CR32","doi-asserted-by":"publisher","first-page":"e001131","DOI":"10.1136\/rmdopen-2019-001131","volume":"6","author":"B Fautrel","year":"2020","unstructured":"Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F, Kannowski CL, Nicolay C, Kadziola Z, De La Torre I, Fleischmann R (2020) RMD Open 6:e001131","journal-title":"RMD Open"},{"key":"5815_CR33","doi-asserted-by":"publisher","first-page":"106549","DOI":"10.1016\/j.intimp.2020.106549","volume":"84","author":"A Yaekura","year":"2020","unstructured":"Yaekura A, Yoshida K, Morii K, Oketani Y, Okumura I, Kaneshiro K, Shibanuma N, Sakai Y, Hashiramoto A (2020) Chronotherapy targeting cytokine secretion attenuates collagen-induced arthritis in mice. Int Immunopharmacol 84:106549","journal-title":"Int Immunopharmacol"},{"key":"5815_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, Zhang X, Zuckerman SH, Taylor PC (2019) Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther 21:183","journal-title":"Arthritis Res Ther"},{"key":"5815_CR35","doi-asserted-by":"publisher","first-page":"R199","DOI":"10.1186\/ar4037","volume":"14","author":"AD Cook","year":"2012","unstructured":"Cook AD, Pobjoy J, Steidl S, D\u00fcrr M, Braine EL, Turner AL, Lacey DC, Hamilton JA (2012) Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther 14:R199","journal-title":"Arthritis Res Ther"},{"key":"5815_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/annrheumdis-2012-201703","volume":"72","author":"AD Cook","year":"2013","unstructured":"Cook AD, Pobjoy J, Sarros S, Steidl S, D\u00fcrr M, Lacey DC, Hamilton JA (2013) Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann Rheum Dis 72:265\u2013270","journal-title":"Ann Rheum Dis"},{"key":"5815_CR37","doi-asserted-by":"publisher","first-page":"8032","DOI":"10.1073\/pnas.0810420106","volume":"106","author":"M Tsuda","year":"2009","unstructured":"Tsuda M, Masuda T, Kitano J, Shimoyama H, Tozaki-Saitoh H, Inoue K (2009) IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc Natl Acad Sci U S A 106:8032\u20138037","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5815_CR38","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1073\/pnas.0501634102","volume":"102","author":"FY Tanga","year":"2005","unstructured":"Tanga FY, Nutile-McMenemy N, DeLeo JA (2005) The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 102:5856\u20135861","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5815_CR39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/jcm8060831","volume":"8","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, Zhu B, Quebe AK, Gaich CL, Zhang X, Dickson CL, Schlichting DE, Patel H, Durand F, Emery P (2019) Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial. J Clin Med 8:831","journal-title":"J Clin Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05815-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05815-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05815-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T20:08:40Z","timestamp":1626725320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05815-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5815"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05815-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SA has received speakers\u2019 fees from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Janssen, Takeda, and UCB Japan. NT has received research support and\/or speakers\u2019 fees from AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Mitsubishi Tanabe, Asahi Kasei, Astellas, Pfizer, Janssen, Daiichi-Sankyo, Takeda, Eli Lilly, Novartis, and UCB Japan. TN has received a speakers\u2019 fee from Eli Lilly. YH has received speakers\u2019 fees from AbbVie, Asahi Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Pfizer, and UCB Japan. YY has received a speakers\u2019 fee from Asahi Kasei. MS has received speakers\u2019 fees from Bristol-Myers Squibb, Eisai, and Asahi Kasei. NI has received grant\/research support, consulting fees, and\/or speakers\u2019 fees from AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kaken, Mitsubishi Tanabe, Ono, Otsuka, Pfizer, Taisho Toyama, and Takeda. SI has received grant\/research support from Zimmer Biomet. TK has received grant\/research support and\/or speakers\u2019 fees from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sanksyo, Eli Lilly, Janssen, Mitsubishi Tanabe, Novartis, Pfizer, and Takeda. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Nagoya University Graduate School of Medicine (2011\u20131164) and complied with the principles set forth in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publication"}}]}}